Acceder

Farmas USA

135K respuestas
Farmas USA
86 suscriptores
Farmas USA
Página
12,261 / 16,989
#98081

Re: Farmas USA

HZNP creo que quieres decir 15,80, ¿no?

«Después de nada, o después de todo/ supe que todo no era más que nada.»

#98082

Re: Farmas USA

ONVO

Suele funcionar corto a primera hora; luego suele recuperar la subida y caer al día siguiente o al otro.

presenting the first data showing survival and sustained functionality of its 3D bioprinted human liver tissue when implanted into animal models. This data is being presented at the TERMIS-Americas Meeting in San Diego.

Organovo implanted its 3D bioprinted human liver tissue patches onto the livers of NOD/SCID mice. The tissue was composed of human hepatocytes and select non-parenchymal cells. Function of the 3D bioprinted human liver tissue patches was seen via detection of human albumin, alpha-1-anti-trypsin and fibrinogen in the circulating blood of the mice as early as seven days and for at least 28 days post-implantation. Histopathologic evaluation of the implanted therapeutic tissue revealed retention of the bioprinted cellular organization through 28 days post-implantation, with robust staining for key human metabolic enzymes associated with inborn errors of metabolism, such as Fumarylacetoacetate Hydrolase (FAH) deficiency and Ornithine Transcarbamylase (OTC) deficiency. The tissues remained intact on the animal liver and were well tolerated by the animals. Taken together, these data support further preclinical development of Organovo’s 3D bioprinted liver tissue for therapeutic use.

«Después de nada, o después de todo/ supe que todo no era más que nada.»

#98083

Re: Farmas USA

Jjjjjjj no con 14,80 saco 500$ y cierto el año....😉

#98084

Re: Farmas USA

KITE

Kite Pharma, Inc. (KITE) and Vitruvian Networks, Inc., a pioneering cell and gene therapy software and analytics platform company co-founded by GE Ventures and the Mayo Clinic, announced today a strategic partnership to create a software solution to support commercial availability of T-cell therapies. Together, the parties will design and develop a platform for patients, physicians and treatment centers that enables commercial-scale ordering, logistics, monitoring and delivery of autologous cell therapies if they are FDA-approved, including axicabtagene ciloleucel (formerly known as KTE-C19), Kite’s lead investigational engineered T-cell therapy for aggressive non-Hodgkin lymphoma.

http://finance.yahoo.com/news/kite-pharma-vitruvian-networks-enter-133000240.html?soc_src=social-sh&soc_trk=tw

«Después de nada, o después de todo/ supe que todo no era más que nada.»

#98085

Re: Farmas USA

Gracias Ana. Si, va como una bala, está en modo Celator. Iluso de mi, esta de corregir nada. He comprado más a 14.4 en pm. No se si he hecho bien, pero no he podido evitarlo!! En vez de doblar posición la he aumentado un 50%.

Mañana tendré más liquidez, si se desboca supongo que sujetaré el dedo, pero si cae compraré una vez más y lo dejaré estar. Espero no estropearlo con estas entradas.

AKAO

#98086

Re: Farmas USA

DVAX
Sigues pensando entrar en Dvax en 4 pavos?

#98087

Re: Farmas USA

Error ....15,80 es mi orden ....modo móvil y comida ....mal plan....🤔

#98088

Re: Farmas USA

Si.....

Te puede interesar...

- No hay entradas a destacar -

- No hay entradas a destacar -

Brokers destacados